Ronald Evans

Ronald Evans

Directeur/Membre du Conseil chez
The Salk Institute for Biological Studies
76 ans
Health Technology
Commercial Services
Consumer Services

Profil

Ronald M.
Evans
is the founder of Ligand Pharmaceuticals, Inc. (1987), Syndax Pharmaceuticals, Inc. (2005), Synchronicity Pharma, Inc. (2008), Mitobridge, Inc. (2013), and Metacrine, Inc. (2014).
He is also the founder of Xenopharm, Inc., X-Ceptor Therapeutics, Inc., XTuit Pharmaceuticals, Inc. Dr. Evans's current jobs include Director & Professor at The Salk Institute for Biological Studies, Director at American Association for Cancer Research, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, and Member at National Academy of Medicine (United States).
Dr. Evans received his doctorate degree from the University of California, Los Angeles in 1974 and his undergraduate degree from the same university in 1970.

Postes actifs de Ronald Evans

SociétésPosteDébut
Directeur/Membre du Conseil -
Corporate Officer/Principal 25/01/2010
Corporate Officer/Principal 25/01/2010
Corporate Officer/Principal 25/01/2010
Directeur/Membre du Conseil -

Anciens postes connus de Ronald Evans

SociétésPosteFin
METACRINE, INC. Fondateur 23/03/2023
Fondateur -
Fondateur -
Fondateur -
░░░░░░░░░░ ░░░░ ░░░░░░░░░ -
Voir l'expérience en détail de Ronald Evans

Formation de Ronald Evans

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

88

Relations au 1er degré

14

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées14

Health Technology

Consumer Services

Health Technology

Commercial Services

Consumer Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Ronald Evans
- 40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT